Trial Profile

Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device (DOSED)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPC 1 (Primary)
Indications Spinal cord injuries
Focus Adverse reactions
Acronyms DOSED
Sponsors Lineage Cell Therapeutics

Most Recent Events

17 Feb 2026 Last checked against ClinicalTrials.gov: US National Institutes of Health.
06 Nov 2025 According to Lineage Cell Therapeutics media release, California Institute for Regenerative Medicine (CIRM) continues to review application for a CLIN2 clinical grant to support DOSED study of OPC1.
06 Nov 2025 Results presented in a Lineage Cell Therapeutics media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com